Suppr超能文献

阴道原发性浸润性鳞状细胞癌的放化疗

Chemoradiation for primary invasive squamous carcinoma of the vagina.

作者信息

Dalrymple J L, Russell A H, Lee S W, Scudder S A, Leiserowitz G S, Kinney W K, Smith L H

机构信息

University of California at Davis, Medical Center, Division of Gynecologic Oncology, Sacramento, CA 95817, USA.

出版信息

Int J Gynecol Cancer. 2004 Jan-Feb;14(1):110-7. doi: 10.1111/j.1048-891x.2004.014066.x.

Abstract

OBJECTIVE

To report outcomes for patients with primary, invasive, squamous carcinoma of the vagina treated with chemoradiation.

METHODS

Between 1986 and 1996, 14 patients were treated with primary therapy consisting of synchronous radiation and chemotherapy. Patients were judged not to be surgical candidates based on tumor size, location, and concerns related to urinary, bowel, or sexual function. Three patients were FIGO stage I, ten patients stage II, and one patient stage III. Radiation consisted of teletherapy alone (six patients) or in combination with intravaginal brachytherapy (eight patients). Total radiation dose ranged from 5700 to 7080 cGy (median 6300 cGy). Chemotherapy consisted of 5-fluorouracil alone (seven patients), or with cisplatin (six patients) or mitomycin-C (one patient).

RESULTS

One patient failed locally at 7 months and died of disease at 11 months. Four patients died of intercurrent illness (46, 92, 104, 109 months) and nine are alive and cancer-free 74-168 months after treatment (median 100 months). There were no vesicovaginal or enterovaginal fistulae.

CONCLUSIONS

Radiation with synchronous chemotherapy is an effective treatment for squamous carcinoma of the vagina. Cancer control outcomes compare favorably with previously published results employing higher dose radiation as monotherapy.

摘要

目的

报告接受放化疗的原发性浸润性阴道鳞状癌患者的治疗结果。

方法

1986年至1996年间,14例患者接受了同步放疗和化疗的初始治疗。根据肿瘤大小、位置以及与泌尿、肠道或性功能相关的问题,判断患者不适合手术。3例患者为国际妇产科联盟(FIGO)I期,10例为II期,1例为III期。放疗包括单纯远距离放疗(6例患者)或联合阴道内近距离放疗(8例患者)。总放疗剂量为5700至7080厘戈瑞(中位数6300厘戈瑞)。化疗包括单独使用5-氟尿嘧啶(7例患者),或联合顺铂(6例患者)或丝裂霉素-C(1例患者)。

结果

1例患者在7个月时局部复发,11个月时死于疾病。4例患者死于并发疾病(分别在46、92、104、109个月),9例患者在治疗后74至168个月存活且无癌(中位数100个月)。未出现膀胱阴道瘘或肠阴道瘘。

结论

同步化疗放疗是治疗阴道鳞状癌的有效方法。癌症控制结果与之前发表的采用更高剂量放疗作为单一疗法的结果相比更有利。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验